NM-2201

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
NM-2201
NM-2201 structure.png
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC24H22FNO2
Molar mass375.443 g·mol−1
3D model (JSmol)

NM-2201 (also known as CBL-2201) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB1 and CB2 receptors with low nanomolar affinity.[1][2][3][4]

Pharmacology[edit]

NM-2201 acts as a full agonist with a binding affinity of 0.332 nM at CB1 and 0.732 nM at CB2 cannabinoid receptors.[5] It has been linked to serious adverse events in users.[6]

Legal status[edit]

NM-2201 is specifically banned in Sweden,[7] Germany (Anlage II),[8] and Japan[9] but is also controlled in many other jurisdictions under analogue laws.

On May 30, 2018 the United States Drug Enforcement Administration, Department of Justice published a notice of intent to place NM-2201 and 4 other synthetic cannabinoids in schedule I of the Controlled Substances Act. This notice went into effect on June 29, 2018.[10]

Use[edit]

NM-2201 was linked to an incident in December 2015 where 25-30 people in Ocala, FL were taken to hospitals after experiencing seizures.[10]

See also[edit]

References[edit]

  1. ^ Kondrasenko, A.A; Goncharov, E.V; Dugaev, K.P; Rubaylo, A.I (2015). "CBL-2201. Report on a new designer drug: Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate". Forensic Science International. 257: 209–13. doi:10.1016/j.forsciint.2015.08.023. PMID 26386336.
  2. ^ "NM-2201". Cayman Chemical. Retrieved 9 July 2015.
  3. ^ Namera, Akira; Kawamura, Maho; Nakamoto, Akihiro; Saito, Takeshi; Nagao, Masataka (2015). "Comprehensive review of the detection methods for synthetic cannabinoids and cathinones". Forensic Toxicology. 33 (2): 175–194. doi:10.1007/s11419-015-0270-0. PMC 4525208. PMID 26257831.
  4. ^ Shevyrin, Vadim; Melkozerov, Vladimir; Nevero, Alexander; Eltsov, Oleg; Baranovsky, Alexander; Shafran, Yuri (2014). "Synthetic cannabinoids as designer drugs: New representatives of indol-3-carboxylates series and indazole-3-carboxylates as novel group of cannabinoids. Identification and analytical data". Forensic Science International. 244: 263–75. doi:10.1016/j.forsciint.2014.09.013. PMID 25305529.
  5. ^ Hess, Cornelius; Schoeder, Clara T; Pillaiyar, Thanigaimalai; Madea, Burkhard; Müller, Christa E (2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. PMC 4929166. PMID 27429655.
  6. ^ Samra, Kiran; Boon, Ian S; Packer, Gregory; Jacob, Saiju (2017). "Lethal high: Acute disseminated encephalomyelitis (ADEM) triggered by toxic effect of synthetic cannabinoidblack mamba". BMJ Case Reports. 2017: bcr–2016–218431. doi:10.1136/bcr-2016-218431. PMC 5534782. PMID 28433979.
  7. ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. Retrieved 9 July 2015.
  8. ^ "Gesetz über den Verkehr mit Betäubungsmitteln Anlage II". www.gesetze-im-internet.de (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved 24 October 2016.
  9. ^ Diao, Xingxing; Carlier, Jeremy; Zhu, Mingshe; Pang, Shaokun; Kronstrand, Robert; Scheidweiler, Karl B; Huestis, Marilyn A (2016). "In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201)". Forensic Toxicology. 35 (1): 20–32. doi:10.1007/s11419-016-0326-9. PMC 5342258. PMID 28286577.
  10. ^ a b "2018 - Temporary Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA Into Schedule I". www.deadiversion.usdoj.gov. Retrieved 2018-06-15.